vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $18.6M, roughly 1.4× ENANTA PHARMACEUTICALS INC). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -64.1%, a 103.4% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs 9.8%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-11.8M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs 4.5%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
ENTA vs WTBA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $26.9M |
| Net Profit | $-11.9M | $10.6M |
| Gross Margin | — | — |
| Operating Margin | -60.5% | 50.0% |
| Net Margin | -64.1% | 39.2% |
| Revenue YoY | 9.8% | 16.6% |
| Net Profit YoY | 46.4% | 34.8% |
| EPS (diluted) | $-0.42 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $18.6M | $24.2M | ||
| Q3 25 | $15.1M | $25.0M | ||
| Q2 25 | $18.3M | $23.8M | ||
| Q1 25 | $14.9M | $23.1M | ||
| Q4 24 | $17.0M | $20.9M | ||
| Q3 24 | $14.6M | $20.3M | ||
| Q2 24 | $18.0M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-11.9M | $7.4M | ||
| Q3 25 | $-18.7M | $9.3M | ||
| Q2 25 | $-18.3M | $8.0M | ||
| Q1 25 | $-22.6M | $7.8M | ||
| Q4 24 | $-22.3M | $7.1M | ||
| Q3 24 | $-28.8M | $6.0M | ||
| Q2 24 | $-22.7M | $5.2M |
| Q1 26 | — | 50.0% | ||
| Q4 25 | -60.5% | 39.6% | ||
| Q3 25 | -121.6% | 45.8% | ||
| Q2 25 | -103.2% | 43.4% | ||
| Q1 25 | -164.3% | 43.4% | ||
| Q4 24 | -138.8% | 30.9% | ||
| Q3 24 | -204.4% | 36.6% | ||
| Q2 24 | -134.6% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -64.1% | 30.7% | ||
| Q3 25 | -123.6% | 37.3% | ||
| Q2 25 | -99.7% | 33.5% | ||
| Q1 25 | -151.7% | 34.0% | ||
| Q4 24 | -131.4% | 34.0% | ||
| Q3 24 | -197.3% | 29.3% | ||
| Q2 24 | -126.1% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-0.42 | $0.44 | ||
| Q3 25 | $-0.88 | $0.55 | ||
| Q2 25 | $-0.85 | $0.47 | ||
| Q1 25 | $-1.06 | $0.46 | ||
| Q4 24 | $-1.05 | $0.41 | ||
| Q3 24 | $-1.36 | $0.35 | ||
| Q2 24 | $-1.07 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $270.7M |
| Total Assets | $329.5M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $37.4M | $471.1M | ||
| Q3 25 | $32.3M | $232.9M | ||
| Q2 25 | $44.8M | $345.2M | ||
| Q1 25 | $60.2M | — | ||
| Q4 24 | $84.3M | $243.5M | ||
| Q3 24 | $37.2M | — | ||
| Q2 24 | $35.8M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $126.6M | $266.0M | ||
| Q3 25 | $64.7M | $255.1M | ||
| Q2 25 | $79.3M | $240.9M | ||
| Q1 25 | $93.5M | $237.9M | ||
| Q4 24 | $111.8M | $227.9M | ||
| Q3 24 | $128.8M | $235.4M | ||
| Q2 24 | $148.9M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $329.5M | $4.1B | ||
| Q3 25 | $280.7M | $4.0B | ||
| Q2 25 | $301.0M | $4.1B | ||
| Q1 25 | $323.0M | $4.0B | ||
| Q4 24 | $348.6M | $4.0B | ||
| Q3 24 | $376.7M | $4.0B | ||
| Q2 24 | $398.8M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $12.9M |
| Free Cash FlowOCF − Capex | $-11.8M | $12.4M |
| FCF MarginFCF / Revenue | -63.6% | 46.0% |
| Capex IntensityCapex / Revenue | 0.8% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $-11.7M | $46.5M | ||
| Q3 25 | $-6.5M | $11.4M | ||
| Q2 25 | $17.5M | $13.5M | ||
| Q1 25 | $-13.5M | $9.7M | ||
| Q4 24 | $-16.8M | $39.8M | ||
| Q3 24 | $-10.4M | $12.9M | ||
| Q2 24 | $-14.8M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | $-11.8M | $43.2M | ||
| Q3 25 | $-7.9M | $10.8M | ||
| Q2 25 | $17.4M | $12.8M | ||
| Q1 25 | $-16.0M | $8.3M | ||
| Q4 24 | $-25.5M | $13.7M | ||
| Q3 24 | $-19.4M | $7.0M | ||
| Q2 24 | $-21.3M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | -63.6% | 178.3% | ||
| Q3 25 | -52.5% | 43.0% | ||
| Q2 25 | 94.7% | 53.6% | ||
| Q1 25 | -107.4% | 35.7% | ||
| Q4 24 | -150.6% | 65.6% | ||
| Q3 24 | -132.5% | 34.2% | ||
| Q2 24 | -118.6% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 0.8% | 13.7% | ||
| Q3 25 | 9.6% | 2.6% | ||
| Q2 25 | 0.8% | 3.2% | ||
| Q1 25 | 17.0% | 6.5% | ||
| Q4 24 | 51.6% | 125.3% | ||
| Q3 24 | 61.3% | 29.4% | ||
| Q2 24 | 36.4% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
